MannKind Conference on Insulin Inhalers Has Investors Breathing Easy: StockTwits

NEW YORK (TheStreet) -- Analysts and investors are gaining confidence in MannKind  (MNKD). CEO Alfred Mann updated the investment community at a health care conference Wednesday about the progress of the biotech company's insulin inhaler, Afrezza, which is seeking FDA approval. And investors on StockTwits.com were impressed by his speech and promise of partnerships to distribute the drug.

$MNKD Josh Here @mantrade Conference Quote "There will be 2 partners, global and US." Bullish

? brad simon (@greglawguy) May. 14 at 01:41 PM

The stock was the most-discussed ticker on StockTwits.com Wednesday afternoon. Bullish sentiment increased to 96%, according to site analytics. Shares rose nearly 7% by the end of trading, closing at $7.01 on Wednesday.

Investors said that Mann sounded confident that FDA approval would come soon. They argued that a drug that would allow diabetics to forgo needles, at least at mealtimes, would be considered needed enough to warrant fast track approval. An unwillingness to administer repeated shots is a main reason diabetics do not comply with dosing guidelines.

$MNKD @dollarbills288 No More Needles- This Will Revolutionize The Diabetes Market. AGREE.

? todd pressman (@supermanjoe) May. 14 at 02:35 PM

Initially, investors raised some concerns that the FDA would focus on lung complications from the insulin inhaler and not approve the product for sale in the U.S. However, an FDA committee voted unanimously last month to approve the drug for people with type 2 diabetes. All but one committee member recommended approving the drug for type 2 diabetes.

$MNKD Whether it goes down or up, you're still going to make money - as long as you're in. FDA approval could come at anytime.

? Justin Lynch (@MyPlainUsername) May. 14 at 02:23 PM

An analyst upgrade also helped fuel bullish sentiment. On Wednesday, Piper Jaffray upgraded MannKind from underweight to neutral. It raised its price target $4.50 to $6.50.

Some investors pointed out that MannKind is still something of a speculative lottery stock. The company's success rides nearly entirely on Afrezza approval, as it has only two drugs in the pipeline, both inhaled forms of insulin. If the FDA decides that lung complications are too severe to approve the drug, then Mannkind would have little value.

@Blakej01 The double or triple break into 7's feels good for longs.Piper upgrade was silly but at least an upgrade. Still speculative play

? Danny Beee (@CashSteroids) May. 14 at 01:31 PM

But few investors saw that happening after hearing Wednesday's conference.

@Blakej01 Partnership announcement = boom, FDA approval = boom. And there will be plenty of other catalysts down the road, IMO.

? Alex Vazquez (@alexvazquez2121) May. 14 at 02:33 PM
 

At the time of publication the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

>>Read More: Why Marissa Mayer Just Bought the Next Snapchat

>>Read More: Why the OpenStack Cloud Bubble Will Soon Burst

>>Read More: Gold ETFs Continue to Inflict Maximum Frustration

More from Opinion

These 5 Tech Giants Still Aren't That Expensive

These 5 Tech Giants Still Aren't That Expensive

Intel CEO Brian Krzanich's Ouster Proves CEOs Aren't Above the Rules

Intel CEO Brian Krzanich's Ouster Proves CEOs Aren't Above the Rules

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others